Figure 2.
Subgroup analysis based on different types of DOACs regarding the risk of fractures of DOACs vs. VKAs in AF patients. AF, atrial fibrillation; DOACs, direct oral anticoagulants; VKAs, vitamin K antagonists; DA, dabigatran; RIV, rivaroxaban; API, apixaban; EDO, edoxaban; CI, confidence interval; SE, standard error; IV, inverse of the variance.